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O B J E C T I V E S The aim of this study was to assess whether residual nonculprit (NC) lesions, deﬁned
as visual diameter stenosis 30% after successful percutaneous coronary intervention, affect the rate of
future events in patients with acute coronary syndromes.
B A C KG ROUND In patients with acute coronary syndromes, approximately one-half of recurrent
events after percutaneous coronary intervention arise from untreated lesions.
METHOD S Patients enrolled in PROSPECT (Providing Regional Observations to Study Predictors of
Events in the Coronary Tree) were divided into 3 groups: those with no NC lesions, 1 NC lesion, or 2
NC lesions. Time to events for major adverse cardiac events was estimated up to 3 years.
R E S U L T S Among 697 patients, 13.3% had no NC lesions, 19.7% had 1 NC lesion, and 67.0% had 2
NC lesions. The median diameter stenoses of the NC lesions in the latter 2 groups were 36.7%
(interquartile range: 31.0% to 43.4%) and 37.4% (interquartile range: 32.0% to 46.5%), respectively (p 
0.22). At least 1 thin-cap ﬁbroatheroma was present in one-half the patients in each group. At 3 years,
the incidence of major adverse cardiac events was 8.5%, 15.2%, and 24.3%, respectively (p 0.0009). NC
lesion–related events occurred in 0%, 5.0%, and 15.9% of patients, respectively (p  0.0001). Of 105 NC
lesion–related clinical events occurring during follow-up, 73 (69.5%) originated from angiographically
evident baseline NC lesions (of which 36 had diameter stenosis 50%), while the other 32 arose from
normal or near normal segments.
CONC L U S I O N S Residual NC lesions are common after percutaneous coronary intervention for
acute coronary syndromes and portend a higher rate of recurrent ischemic events within 3 years,
especially when angiographically more severe. Conversely, the absence of NC lesions by angiography is
highly predictive of freedom from events not related to the originally treated culprit lesion(s). (J Am
Coll Cardiol Img 2012;5:S86–94) © 2012 by the American College of Cardiology Foundation
From the *New York Methodist Hospital, Brooklyn, New York; †Cardiovascular Research Foundation, New York, New York;
‡Columbia University Medical Center, New York, New York; §Vanderbilt University Medical Center, Nashville, Tennessee;
Saint Luke’s Mid American Heart and Vascular Institute, Kansas City, Missouri; ¶North Ohio Heart Center/Elyria Memorial
Hospital Regional Medical Center, Elyria, Ohio; #Aarhus University Hospital, Skejby, Denmark; **Abbott Vascular, Santa
Clara, California; ††Cardiovascular Center Aalst, Aalst, Belgium; and the §§Erasmus University, Thoraxcentrum, Rotterdam,
the Netherlands. Dr. Mintz has received grant support and consulting fees from Volcano; grant support and honoraria from
a
t
i
s
v
n
o
p
f
w
a
(
i
(
u
m
t f
o
v
e
s
a
T
l
f
w
p
q
c
p
virtual histology
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , S U P P L S , 2 0 1 2
M A R C H 2 0 1 2 : S 8 6 – 9 4
Brener et al.
Nonculprit Stenoses in ACS
S87T
he long-term prognosis of patients with
coronary artery disease is highly dependent on
the extent of atherosclerosis (1). Angiographic
studies in small series of patients before and
fter acute coronary syndromes (ACS) have shown
hat a significant proportion of these events can be
ndexed to coronary lesions of mild and moderate
everity (2,3). Registries of patients with ACS
See page S106
suggest that as many as 50% of patients have had
previous events arising from a different coronary site
(4,5), consistent with the growing understanding of
the diffuse nature of atherosclerosis leading to plaque
rupture (6).
In the PROSPECT (Providing Regional Obser-
ations to Study Predictors of Events in the Coro-
ary Tree) study, after successful percutaneous cor-
nary intervention (PCI) of culprit lesions in
atients with ACS, the most powerful predictors of
uture events at untreated nonculprit (NC) lesions
ere large plaque burden, small minimal luminal
rea, and the presence of a thin-cap fibroatheroma
TCFA) as assessed by 3-vessel radiofrequency
ntravascular ultrasound (IVUS)–virtual histology
VH) (7–15). However, whether the presence of
ntreated lesions by angiography, most of which are
ild, can identify patients and lesions predisposed
o future adverse events (arising either from the angio-
graphically evident lesions or from otherwise angio-
graphically silent sites) is unknown. In the present
analysis, we therefore examined whether the pres-
ence of angiographically visible disease indicates
greater underlying atherosclerotic disease burden
and is predictive of subsequent NC lesion–related
events and whether, conversely, the absence of
angiographically visible disease portends a favorable
prognosis.
M E T H O D S
The PROSPECT study has been described in
detail (7). In brief, 697 patients presenting with
ACS (ST-segment elevation myocardial infarction,
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or unstable angina with electrocardiographic
changes) were enrolled after successful PCI of all
lesions believed to be responsible for the clinical
presentation and after completion of any other
planned interventions (culprit lesions). Three-vessel
quantitative coronary angiography (QCA) and
IVUS-VH imaging were then performed, as previ-
ously described (16,17). All residual stenoses after
PCI with visually assessed diameter stenosis (DS)
30% in any coronary vessel were identified before
the performance of QCA. We divided these pa-
tients into 3 groups: those without any residual NC
lesions, those with 1 NC lesion, and those with 2
NC lesions.
Patients were followed for a median of 3.4 years.
The primary endpoint was the occurrence of major
adverse cardiac events (MACE) at 3 years,
consisting of cardiac death, myocardial
infarction, or rehospitalization for unsta-
ble or progressive angina as adjudicated
independently by a committee blinded to
imaging results. Each adverse event was
adjudicated to have arisen from either an
originally treated culprit lesion or an un-
treated NC lesion or was termed indeter-
minate in origin in the absence of
follow-up angiography.
QCA. QCA measurements were per-
ormed over the entire length of the cor-
nary tree (including side branches) in any
essel 1.5 mm in diameter using propri-
tary methods modified from Medis CMS
oftware version 7.0 (Medis Medical Im-
ging Systems, Leiden, the Netherlands).
he reference vessel diameter, minimal
uminal diameter, and DS were calculated
or each vessel. Analysis of all angiographic lesions
ith30% visual DS was pre-specified in the study
rotocol (7).
IVUS and IVUS-VH analysis. Grayscale and radiofre-
uency IVUS of the left main and proximal 6 to 8
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S88mm/s. Offline grayscale and IVUS-VH analysis was
performed using: 1) QCU-CMS (Medis Medical
Imaging Systems) for contouring; 2) pcVH version
2.1 software (Volcano Corporation, Rancho Cor-
dova, CA) for contouring and VH data output; and
3) qVH software (developed within the Cardiovas-
cular Research Foundation) for segmental qualita-
tive assessment and data output. Quantitative IVUS
measurements included external elastic membrane,
luminal, and plaque plus media cross-sectional area
and plaque burden (defined as plaque plus media
divided by external elastic membrane). An IVUS
lesion was defined as a segment with 3 consecu-
tive frames with 40% plaque burden.
IVUS-VH plaque components were reported as
cross-sectional area and percents of total plaque
area. Lesions were classified into 5 main pheno-
types: 1) VH TCFA; 2) thick-cap fibroatheroma;
3) pathological intimal thickening; 4) fibrotic
plaque; and 5) fibrocalcific plaque (18). High-risk
lesions were defined as those with plaque burden
70%, and/or minimal luminal area 4 mm2,
nd/or VH TCFA.
Statistical analysis. Continuous variables (presented
s medians with interquartile ranges [IQRs]) and
ategorical variables (presented as proportions) were
nalyzed using analysis of variance and chi-square
ests, respectively. Kaplan-Meier time-to-event es-
Table 1. Baseline Characteristics of Patients According to the N
No NC Lesions
(n  93)
Age (yrs) 56.1 (47.9–63.8)
Men 69.9% (65/93)
Body mass index (kg/m2) 27.9 (25.7–30.5)
Any diabetes 15.2% (14/92)
Metabolic syndrome 49.5% (45/91)
Prior MI 6.5% (6/92)
Prior PCI 7.5% (7/93)
Hypertension 43.0% (40/93)
Hypercholesterolemia 41.0% (34/83)
History of tobacco use 1 month 40.2% (37/92)
Presentation: STEMI 24 h 31.2% (29/93)
Presentation: NSTEMI 59.1% (55/93)
Estimated CrCl  60 ml/min 2.3% (2/87)
HDL cholesterol (mg/dl) 38.6 (34.0–45.0)
LDL cholesterol (mg/dl) 99.7 (76.1–134.6)
Metabolic syndrome 49.5% (45/91)
1 culprit vessel treated 79.6% (74/93)
Framingham score 7 (4–8)
CRP, day 0 (mg/dl) 5.9 (1.8–18.4)
Values are median (interquartile range) or % (n/N).
CrCl  creatinine clearance; CRP  C-reactive protein; MI  myocardial infarcPCI  percutaneous coronary intervention; STEMI  ST-segment elevation myocardimates were compared using log-rank tests. A Cox
egression model using the clinical and IVUS pa-
ameters found to be predictive in PROSPECT was
sed to check for the independent predictive value
f NC lesions, according to degree (30% to 50%,
0% to 70%, and 70%). All analyses were per-
ormed using SAS version 9.0 (SAS Institute Inc.,
ary, North Carolina). Two-sided p values  0.05
ere considered significant.
R E S U L T S
Patients and baseline characteristics. After PCI of all
culprit lesions in 697 patients, 93 patients (13.3%)
had no residual NC lesions 30%, 137 patients
(19.7%) had 1 residual NC lesion, and 467 patients
(67.0%) had 2 residual NC lesions (mean 3.6 
1.6 lesions per patient; 1,637 total lesions). The
baseline characteristics of these 3 groups are shown
in Table 1. An increasing number of residual
angiographic NC lesions was associated with ad-
vanced age, hypertension, kidney dysfunction, and a
larger number of coronary arteries containing
treated culprit lesions.
QCA. The median DS of 1,824 angiographically
evident NC lesions was 37.4% (IQR: 31.8% to
46.4%). The NC lesions in patients with only 1
such lesion had a larger reference vessel diameter
er of Angiographic NC Lesions
1 NC Lesion
(n  137)
>2 NC Lesions
(n  467) p Value
57.6 (48.8–65.3) 58.8 (51.8–67.7) 0.004
76.6% (105/137) 77.1% (360/467) 0.33
28.7 (25.1–31.2) 27.7 (24.9–31.2) 0.42
19.0% (26/137) 17.0% (79/465) 0.75
45.5% (55/121) 49.4% (224/453) 0.73
8.8% (12/137) 11.9% (55/464) 0.24
9.5% (13/137) 12.2% (57/466) 0.34
36.8% (50/136) 49.8% (230/462) 0.02
43.9% (54/123) 44.8% (191/426) 0.81
52.9% (72/136) 47.7% (219/459) 0.17
34.3% (47/137) 28.9% (135/467) 0.47
65.0% (89/137) 67.0% (313/467) 0.34
4.6% (6/131) 13.7% (60/439) 0.0003
38.6 (32.0–45.0) 38.6 (34.0–47.0) 0.43
100.1 (80.2–127.2) 100.7 (80.2–127.2) 0.97
45.0% (58/129) 49.4% (224/453) 0.66
81.6% (111/136) 67.5% (315/467) 0.001
6 (4–9) 7 (5–9) 0.15
7.0 (2.4–17.5) 8.1 (2.6–19.2) 0.62
NC  nonculprit; NSTEMI  non–ST-segment elevation myocardial infarction;umb
tion;
ial infarction.
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S89than in those with multiple NC lesions (median
2.42 mm [IQR: 2.04 to 2.93 mm] vs. 2.25 mm
[IQR: 1.85 to 2.77 mm], p  0.01), a larger
minimal luminal diameter (median 1.59 mm [IQR:
1.16 to 2.93 mm] vs. 1.40 mm [IQR: 1.05 to 1.83
mm], p  0.03), but similar DS (median 36.7%
[IQR: 31.0% to 43.4%] vs. 37.4% [IQR: 32.0% to
46.5%], p  0.22). In these 2 groups, 15.6% (n 
9, 19 lesions) and 49.2% (n  229, 317 lesions)
f patients, respectively, had lesions with DS 
0% (p  0.0001), and 6.6% (n  8, 8 lesions)
nd 13.5% (n  63, 66 lesions) of patients,
espectively, had lesions with DS  70% (p 
.04). There were no other substantial differences
n angiographic morphological characteristics of
he NC lesions between the 2 groups.
VH and grayscale IVUS analysis. There were 4.0
IQR: 3.0 to 6.0), 4.5 (IQR: 3.0 to 6.0), and 5.0
IQR: 4.0 to 6.0) IVUS-defined NC lesions per
atient in the 3 groups, respectively (p  0.0007).
he VH and grayscale IVUS data in the 3 groups
ppear in Table 2 and Figure 1. Patients with more
C lesions had greater total plaque burden, a
igher incidence of lesions with plaque burden
70%, a higher incidence of lesions with minimal
uminal area 4 mm2, and greater total necrotic
core volume. As the number of angiographic NC
lesions increased, a greater proportion of these
Table 2. Baseline Grayscale and Radiofrequency IVUS Findings
No NC Lesions
(n  87)
Number of IVUS NC lesions per patient 4 (3–6)
% plaque volume per patient 48.3 (45.2–50.2)
EEM CSA (mm2) per patient 15.9 (13.8–18.4)
Luminal CSA (mm2) per patient 8.1 (7.0–9.6)
Plaque  media CSA (mm2) per patient 7.5 (6.7–9.1)
1 lesion with MLA  4 mm2 33.3% (29/87)
1 lesion with plaque burden  70% 21.8% (19/87)
(n  80)
Number of TCFAs per patient 1 (0–1.5)
1 TCFA per patient 53.8% (43/80)
Necrotic core volume (mm3) per patient 19.4 (9.3–43.8)
% necrotic core volume per patient 12.7 (8.2–17.1)
Dense calcium volume (mm3) per patient 7.6 (2.9–18.5)
% dense calcium volume per patient 4.6 (2.6–8.0)
Fibrous tissue volume (mm3) per patient 121.1 (54.0–210.1
% ﬁbrous tissue volume per patient 60.2 (54.6–64.5)
Fibrofatty volume (mm3) per patient 31.8 (16.5–71.4)
% ﬁbrofatty volume per patient 19.2 (13.9–26.4)
Values are median (interquartile range) or % (n/N).
CSA  cross-sectional area; EEM  external elastic membrane; IVUS  intravaﬁbroatheroma.patients met at least 1 of the IVUS-VH criteria for
high-risk lesions (p  0.003).
Clinical outcomes. At 3 years, the incidence of any
ACE (arising from original treated culprit le-
ions, NC lesions, or undetermined sites) was 8.5%,
5.2%, and 24.3%, respectively (p  0.0009) (Fig. 2).
atients without angiographically evident NC
esions had 65% fewer events than those with at
east 1 residual NC lesion (hazard ratio: 0.35;
5% CI: 0.16 to 0.74; p  0.004). As shown in
able 3, the greater rate of events in patients with
ore residual angiographic NC lesions was pre-
ominantly driven by rehospitalization for unsta-
le or progressive angina, leading to more fre-
uent revascularization procedures. The 3 groups
id not significantly differ with respect to the rate
f recurrent events attributed to the initially
reated culprit lesion(s) (p  0.19). In contrast,
C lesion–related events during the 3-year
ollow-up period occurred in 0%, 5.0% (n  6),
nd 15.9% (n  68) of patients with 0, 1, and 2
aseline untreated angiographic NC lesions, re-
pectively (p  0.0001).
A total of 105 lesions resulted in NC lesion–
related clinical events during follow-up in 74
patients with repeat angiography during the
event. Among them, 73 NC lesion–related events
arose from lesions that had been classified at
rding to the Number of Angiographic Nonculprit Lesions
1 NC Lesion
(n  129)
>2 NC Lesions
(n  444) p Value
5 (3–6) 5 (4–6) 0.0007
48.8 (46.4–51.6) 49.6 (47.2–52.6) 0.0003
16.5 (14.3–19.0) 16.1 (13.9–18.5) 0.19
8.7 (7.1–9.8) 7.9 (6.7–9.3) 0.03
8.2 (6.8–9.4) 7.9 (6.7–9.3) 0.25
43.4% (72/129) 63.3% (281/444) 0.0001
27.9% (36/129) 37.2% (165/444) 0.007
(n  121) (n  408)
0 (0–1) 1 (0–2) 0.07
46.3% (56/121) 56.1% (229/408) 0.16
29.5 (11.8–49.9) 40.7 (20.4–77.2) 0.0001
10.0 (6.3–16.2) 12.4 (8.1–17.9) 0.03
11.8 (4.1–25.0) 17.8 (8.0–37.8) 0.0001
3.9 (2.3–6.9) 5.5 (3.2–9.3) 0.002
161.6 (83.0–278.3) 192.5 (112.2–313.6) 0.0001
60.5 (56.9–65.0) 59.5 (54.3–63.3) 0.01
52.6 (22.9–96.7) 66.0 (30.9–107.6) 0.0001
20.8 (15.9–28.9) 19.8 (14.8–26.0) 0.30
r ultrasound; MLA  minimal luminal area; NC  nonculprit; TCFA  thin-capAcco
)
scula
roa
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , S U P P L S , 2 0 1 2
M A R C H 2 0 1 2 : S 8 6 – 9 4
Brener et al.
Nonculprit Stenoses in ACS
S90baseline as angiographically evident NC lesions
(representing 69.5% of all lesions causing these
events and 4.0% of the 1,824 NC lesions exam-
ined), while 32 NC lesion–related events (30.5%)
arose from segments of the coronary tree that
were angiographically normal or minimally dis-
Figure 1. Incidence of High-Risk Characteristics of Lesions Dete
MLA  minimal luminal area; NC  nonculprit; TCFA  thin-cap ﬁb
Figure 2. Cumulative Incidence of Major Adverse Cardiac Event
Number of Nonculprit lesionsMACE  major adverse cardiac event.eased at baseline (visually estimated DS 30%).
All 32 of these events arose from the coronary
vessels of patients with 1 or more baseline iden-
tified NC lesions. Among the angiographically
evident residual baseline NC lesions that did
result in future unanticipated MACEs, those
by Intravascular Ultrasound
theroma.
the 3 Groups, Based on the Presence andcteds in
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S91with DS 50% on QCA, although relatively
ncommon, were more frequently associated with
ubsequent NC lesion–related events than less
evere NC lesions (36 of 336 [10.7%] vs. 37 of
,488 [2.4%], respectively, p  0.0001). By
ultivariate analysis, NC lesions remained highly
redictive of MACEs (HR: 3.06; 95% CI: 1.07 to
.75; p  0.04 for 30% to 50%; HR: 6.27; 95%
I: 2.20 to 17.90; p  0.0006 for 50% to 70%;
nd HR: 5.63; 95% CI: 1.80 to 17.56; p  0.003
or 70%). Insulin-dependent diabetes and
plaque burden  70% were also independently
associated with MACEs.
D I S C U S S I O N
The principal findings from this study are as fol-
lows. First, approximately 87% of all patients with
ACS had at least 1 visually evident angiographic
NC lesion with DS 30% after successful PCI,
most of which were mild in severity (median DS
37.4%). Second, the presence and number of an-
giographic residual NC lesions were correlated with
higher risk clinical characteristics, more extensive
and severe underlying atherosclerosis and amount of
necrotic core, and a significantly higher rate of
Table 3. MACEs at 3 Years*
Event
No NC Lesions
(n  93)
Any MACEs
Cardiac death 1.2% (1)
Cardiac arrest 0.0% (0)
Myocardial infarction 2.5% (2)
Rehospitalization 6.0% (5)
MACEs (composite of above) 8.5% (7)
Revascularization (PCI or CABG) 6.0% (5)
NC lesion–related MACEs
Cardiac death 0.0% (0)
Cardiac arrest 0.0% (0)
Myocardial infarction 0.0% (0)
Rehospitalization 0.0% (0)
MACEs (composite of above) 0.0% (0)
Revascularization (PCI or CABG) 0.0% (0)
Indeterminate MACEs
Cardiac death 1.2% (1)
Cardiac arrest 0.0% (0)
Myocardial infarction 1.2% (1)
Rehospitalization 0.0% (0)
MACEs (composite of above) 1.2% (1)
Revascularization (PCI or CABG) 0.0% (0)
Values are % (n). *Some patients had both culprit lesion–related and NC lesion
CABG  coronary artery bypass grafting; MACE  major adverse cardiac eventMACEs during 3-year follow-up, predominantlyrehospitalization for severe angina. Third, among
residual NC lesions, although only about 20% had
baseline DS50%, future MACEs were more than
4 times as likely to arise from these lesions than
from those with DS of 30% to 50%. Last, con-
versely, in patients without angiographically visible
NC lesions, no events related to untreated segments
of the coronary tree occurred within 3 years, an
important favorable prognostic observation.
In prior ACS studies, only lesions with DS
50% were considered to be clinically relevant
(19–21), despite the well-described observation
that future ACS most frequently arises from seg-
ments of more mild angiographic disease (2,3). In
the present analysis, to provide a clinically relevant
context, we prospectively identified essentially all
untreated atherosclerotic lesions that were angio-
graphically evident, defined as those with visually
estimated DS of at least 30%, and assessed their
future prognostic significance. Although in the
overall study population, approximately 1 in 5
patients had recurrent MACEs by 3 years, patients
without angiographically evident NC lesions had a
much lower adverse event rate (65% reduction), and
strikingly, not a single event in these patients arose
1 NC Lesion
(n  137)
>2 NC Lesions
(n  467) p Value
0.8% (1) 2.3% (10) 0.48
0.0% (0) 0.7% (3) 0.48
1.6% (2) 4.0% (17) 0.37
12.8% (16) 21.2% (92) 0.001
15.2% (19) 24.3% (106) 0.001
12.0% (14) 12.9% (90) 0.0009
0.0% (0) 0.0% (0) NA
0.0% (0) 0.0% (0) NA
0.8% (1) 1.3% (5) 0.59
4.2% (5) 14.9% (64) 0.0001
5.0% (6) 15.9% (68) 0.0001
3.3% (4) 14.8% (63) 0.0001
0.8% (1) 2.1% (9) 0.57
0.0% (0) 0.2% (1) 0.78
0.0% (0) 0.2% (1) 0.28
0.0% (0) 1.2% (5) 0.29
0.8% (1) 3.5% (15) 0.17
0.0% (0) 0.0% (0) NA
ted events.
 not applicable; NC  nonculprit; PCI  percutaneous coronary intervention.–relafrom an untreated segment of the coronary tree.
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S92This angiographic finding is analogous to the pre-
viously reported observation in PROSPECT that
by IVUS, no untreated coronary segment with
plaque burden 40% resulted in MACEs during
the follow-up period (7). Thus, a favorable midterm
(3-year) prognosis for patients with ACS success-
fully treated with PCI in whom no other angio-
graphically evident NC lesions are present may be
expected, especially if the likelihood of culprit lesion
events is low.
The NC lesion–related MACE rate during
follow-up was increased in patients with angio-
graphically evident lesions, most of which arose
from mild lesions (50% stenotic by QCA). In-
deed, 32 of 105 NC lesion–related events (30.5%)
arose from angiographically normal or near normal
segments of the coronary tree. However, although
the number of NC lesions with DS50% on QCA
at baseline that ultimately led to unanticipated
MACEs was relatively small (36 in total), they did
represent one-third of the lesions that caused future
NC lesion–related events. Furthermore, the more
severe lesions (those with DS 50% on QCA) were 4
times as likely to result in MACEs as the more
prevalent milder NC lesions (those with DS of 30%
to 50% on QCA). This finding is consistent with a
prior study by Ellis et al. (22), who found that a DS
50% on QCA in a left anterior descending coro-
nary artery lesion was more predictive of subsequent
anterior wall myocardial infarction than less severe
left anterior descending stenoses. However, approx-
imately two-thirds of NC events in PROSPECT orig-
inated from lesions with angiographically mild
stenosis, confirming the angiographic paradox
between the per lesion risk of events (greater in
angiographically more severe lesions) and the per
patient prevalence of events (most arising from
angiographically milder lesions). It is essential to
realize, however, that regardless of their degrees of
angiographic severity, most NC lesions that resulted
in future unanticipated MACEs had high plaque
burden and/or small minimal luminal areas (7), em-
hasizing the limitations of angiography.
Despite the increased risk for future NC lesion–
elated MACEs in patients with angiographically
ild lesions, neither angiographic severity nor gray-
cale or IVUS-VH characteristics alone, or their
ombination, had high specificity to predict events,
eaning that the vast majority of lesions (detected
y either angiography or IVUS) did not result in
vents during the 3-year follow-up period. One of
he explanations for the poor specificity of the
ngiographic and IVUS identification of lesions fiay relate to the frequent remodeling and healing
f high-risk NC lesions that occur over time (23).
ngiography in ACS may also overestimate the
everity of NC lesions due to vasoconstrictive stim-
li from inflammation and thrombosis (24). Thus,
andomized trials with long-term follow-up are
equired to determine the relative benefits of selec-
ive culprit lesion revascularization compared with
ore complete revascularization (25,26). In con-
rast, the absence of angiographically evident lesions
ad an excellent negative predictive value for free-
om from events unrelated to the initially treated
essels over 3 years, a clinically useful prognostic
ndicator.
It is notable in our analysis that the majority of
dverse cardiac events during follow-up were rehos-
italizations for unstable or severe progressive an-
ina, most of which resulted in repeat revascular-
zation. The presence of NC lesions was associated
trongly with this outcome, suggesting that more
ggressive medical therapy (27) in patients with
hese lesions and/or a selective interventional strat-
gy targeted at high-risk lesions might prevent
hese events. In a meta-analysis of 18 studies of
0,280 patients with ST-segment elevation myo-
ardial infarction undergoing PCI, staged PCI of all
esions resulted in lower early and late mortality
han culprit lesion–only PCI (28). This report,
owever, considered only angiographically moder-
te and severe NC lesions, not every lesion with DS
30%. Park et al. (29) evaluated the need for
linically driven PCI of NC lesions after success-
ul PCI of a culprit lesion in 507 patients over 3
ears. The rate of unplanned PCI was 8% at 1
ear, 14% at 2 years, and 16% at 3 years,
onsistent with our findings. In the FAME
Fractional Flow Reserve Versus Angiography for
ultivessel Evaluation) study, measurement of
ractional flow reserve (FFR) identified lesions
or which PCI could be safely deferred for at least
years (30). However, in this study, a significant
umber of unplanned events arose during
ollow-up from less severe lesions in which FFR
as not performed, presumably the types of
esions identified in PROSPECT that cannot be
dentified by angiography or FFR.
Study limitations. First, the overall rate of events
as low and was driven predominantly by severe
r unstable angina, rather than death or myocar-
ial infarction. Second, the number of patients
ithout any angiographically mild NC lesions (n 
3) was relatively small, rendering many of the
ndings hypothesis generating rather than con-
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S93clusive. Third, median follow-up in PROSPECT
was 3.4 years, and the rate of residual angina is
unknown. The prognostic implications of resid-
ual lesions may change after this interval. Finally,
FFR was not performed in PROSPECT, al-
though on the basis of the 3-vessel baseline IVUS
findings (very few lesions with minimal luminal
areas 3 mm2) (7), it is unlikely that many of
them would have had abnormal coronary flow
reserve.
C O N C L U S I O N S
Despite these limitations, the following lessons
from this PROSPECT report provide important
guidance for patient care. First, approximately 87%
of patients with ACS successfully treated with PCI
had at least 1 angiographically evident untreatedal. A prospective natural-history study
1
1
1
1
2012;5 Suppl S:S62–tion. These patients, particularly those with multi-
ple NC lesions and the minority with 50% DS
severity by QCA, were found to have a higher rate
of recurrent ischemic events over 3 years, predom-
inantly rehospitalization for severe progressive or
unstable angina requiring revascularization, war-
ranting at a minimum intensive medical therapy
and close clinical follow-up.
Second, although the specificity of any given
mild lesion to cause a future ischemic event was
low, the absence of any angiographically evident
NC lesions was predictive of complete 3-year free-
dom from events not related to recurrence at the
original treated culprit lesion sites, an important
favorable prognostic signal.
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